The Magazine for Sleep Professionals
Friday, May 15, 2026
IntelliPAP™ is a new optional tool for physicians to use in noninvasive ventilation for patients with respiratory insufficiency and obstructive sleep apnea (OSA). This innovative device automatically adjusts the positive end-expiratory pressure (PEEP) levels in response to sleep-disordered breathing (SDB) events. To enhance safety, clinicians can set minimum and maximum […]
Sleep Specialists, LLC, developers of the FDA-cleared Zzoma® positional therapy device, and ISD Health Solutions, the leading provider of sleep disorder treatment in the Caribbean, today announced a partnership to bring the benefits of Zzoma to patients suffering from mild to moderate positional obstructive sleep apnea (OSA). This collaboration comes […]
As the prevalence of atrial fibrillation (AF) continues to rise, particularly among the aging population, its connection with obstructive sleep apnea (OSA) has become increasingly evident.1 Patients with AF seeking treatment for OSA often present with a complex medical history that includes a number of comorbidities, such as hypertension, acid […]
Samsung Electronics announced that the sleep apnea feature1 on the Samsung Health Monitor app2 has received De Novo authorization from the U.S. Food and Drug Administration (FDA). This feature, which detects signs of sleep apnea using a compatible Samsung Galaxy Watch and phone, was the first of its kind to be authorized […]
Sleep Specialists, LLC, the manufacturer of Zzoma® positional therapy for obstructive sleep apnea (OSA), and iSleep Physicians, a leading virtual sleep specialist practice, have announced a collaboration to improve access to effective OSA treatment options for patients nationwide, offering a comfortable and potentially mask-free alternative to traditional CPAP therapy. Zzoma […]
– SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care – Part of a two-study registrational Phase 3 program that also includes LunAIRo which began enrollment in September 2023 Apnimed, Inc., […]
Kingman Strohl, MD Obstructive sleep apnea (OSA) is effectively managed by positive airway pressure (PAP) applied to the nose and/or mouth. The principle of PAP is to inflate the critical region of closure in the upper airway, usually at the base of the tongue or the uvula. The effective property […]
By Regina Patrick, RPSGT, RST Obstructive Sleep Apnea and Polycystic Ovary Syndrome Polycystic ovary syndrome (PCOS) is a disorder in which many small fluid-filled sacs (i.e., cysts) develop on a woman’s ovaries and the ovaries produce high levels of male sex hormones (i.e., androgens). PCOS is also associated with insulin […]
Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to treat obstructive sleep apnea (OSA) and related disorders, announced positive topline results from the MARIPOSA Phase 2b trial, an efficacy, safety and dose-finding study of one-month duration. The topline results were positive for the company’s lead candidate for […]
We all know someone who is “supposed” to wear their CPAP machine but doesn’t. The one who went through the process of having a custom dental appliance made but doesn’t bother to wear it. The one who continues to suffer from sleep deprivation because even when they did what they […]
